Pfenex (PFNX) Tops Q4 EPS by 22c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. JNJ
6. PLTR
7. HUM
8. NVDA
9. CSCO
10. KTOS

Go back to Pfenex (PFNX) Tops Q4 EPS by 22c

Pfenex Reports Fourth Quarter and Full Year 2015 Results and Provides Business Update

March 10, 2016 4:05 PM EST

SAN DIEGO, March 10, 2016 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided a business update.

"2015 was a very productive and eventful year for Pfenex," stated Bertrand C. Liang, chief executive officer of Pfenex.  "We signed the collaboration agreement for PF582, our biosimilar candidate to Lucentis, with Hospira, now a subsidiary of Pfizer (together, Pfizer) in February 2015,... More